Kura Oncology, Inc. (NASDAQ:KURA) has been assigned a $18.00 price target by stock analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s target price suggests a potential upside of 14.29% from the stock’s current price.
Several other equities analysts also recently commented on the stock. Cowen and Company started coverage on shares of Kura Oncology in a report on Thursday, September 7th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Saturday, September 9th. ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Finally, Citigroup Inc. upped their price target on shares of Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $17.60.
Kura Oncology (NASDAQ:KURA) opened at $15.75 on Thursday. Kura Oncology has a fifty-two week low of $4.72 and a fifty-two week high of $16.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). sell-side analysts forecast that Kura Oncology will post -1.45 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Kura Oncology, Inc. (KURA) PT Set at $18.00 by Oppenheimer Holdings, Inc.” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/11/18/kura-oncology-inc-kura-pt-set-at-18-00-by-oppenheimer-holdings-inc.html.
A number of hedge funds have recently modified their holdings of the business. Iguana Healthcare Management LLC bought a new position in Kura Oncology in the 3rd quarter worth about $1,346,000. California State Teachers Retirement System grew its stake in Kura Oncology by 24.5% in the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after acquiring an additional 6,200 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Kura Oncology by 61.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock worth $587,000 after acquiring an additional 14,900 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Kura Oncology in the 3rd quarter worth about $802,000. Finally, EAM Investors LLC bought a new position in Kura Oncology in the 3rd quarter worth about $2,884,000. Institutional investors and hedge funds own 39.11% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.